Daytrana Fact Sheet
Shire, marketing exclusivity expires about 2009
Attention Deficit Hyperactivity Disorder in children
Blocks reuptake of norepinephrine and dopamine
Supplied as extended release adhesive patches (to be applied to the hip only) in 10 mg/9 hours, 15 mg/9 hours, 20 mg/9 hours, and 30 mg/9 hours.
- Manufacturer recommends applying the patch 2 hours before an effect is needed. Begin with the 10 mg patch and titrate up to next highest dose weekly until you see a response.
- If a patient has side effects later in the day, you can remove the patch sooner than 9 hours to decrease the duration of action.
- Heat applied to the pad increases speed of absorption markedly.
Most common are decreased appetite, weight loss, tics, nausea, affective lability, application site reaction.
- All stimulants are required to carry a warning about the possibility of sudden death, primarily in children with pre-existing cardiac abnormalities.
- Risk of stimulant abuse. However, diversion is unlikely with Daytrana, because once the patch is removed (for example, at school), it cannot be used either transdermally or orally by anyone else.
- Growth suppression, usually mild, is possible with all stimulants.
- Pregnancy Category C.
Avoid in combination with MAOIs.
Metabolized by the liver, but since it is absorbed directly into the bloodstream there is no first pass effect, allowing relatively low dosages of methylphenidate to be effective.
- Average lag time after patch application before presence of methylphenidate in serum is 3 hours.
- Half-life is 3-4 hours.
Current Issue
Topics
Search
Follow Us
Earn CME Credit Instantly!
Not quite ready for a one-year subscription to The Carlat Psychiatry Report? Need CME credits on a particular topic or on a tight deadline?
Try our A la Carte CME! You can buy single or multiple credits of continuing education, without committing to a year-long newsletter subscription.
Click here to purchase A la Carte CME credits
Already an A la Carte subscriber? Click here to go to your a la carte page
Steve Balt Interviewed by NPR
Our own Steve Balt was interviewed on NPR's "Talk of the Nation" on psychiatry's shift toward drugs and away from talk therapy.
Editor-in-Chief
After 10 years at the helm of TCPR, Dr. Carlat has handed over editor-in-chief duties to Dr. Steve Balt. We’re excited to welcome him aboard! Read More...
The 2012 Carlat Atypical Antipsychotics Table is Now Available!
With all the atypicals on the market, it's hard to keep track of indications, dosages, and all the other relevant facts for each drug. Use this table for summaries on these meds, their uses, their side effects, and a whole slew of other information.
TCPR Continuing Education
Accredited/Approved/Accepted by:
- ACCME
- AMA
- APA
- ABPN
- ANCC
- AAPA